Interleukin-8 (IL-8) Inhibitor Pipeline Insight Report 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Interleukin-8
(IL-8) Inhibitor -Pipeline Insight, 2019” drug pipelines has
been added to ResearchAndMarkets.com’s offering.

Interleukin-8 (IL-8) Inhibitor – Pipeline Insight, 2019 report offers
comprehensive insights of the pipeline (under development) therapeutics
scenario and growth prospects across Interleukin-8 (IL-8) Inhibitor
development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for
Interleukin-8 (IL-8) Inhibitor – Pipeline therapeutics development
coverage provides descriptive product profiles including (but not
limited to) drug description, product development and R&D activities
encompassing clinical and pre-clinical studies, designations,
collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Interleukin-8 (IL-8) Inhibitor pipeline
products by developmental stage, product type, molecule type, and
administration route.

Scope of the report

• Provides a snapshot of the therapeutics pipeline activity for
  Interleukin-8 (IL-8) Inhibitor
• Features the Interleukin-8 (IL-8) Inhibitor pipeline across the
  complete product development cycle including all clinical and
  non-clinical stages
• Offers detailed therapeutic product profiles of Interleukin-8 (IL-8)
  Inhibitor with key coverage of developmental activities including
  licensing & collaboration deals, patent details, designations,
  technologies, indications and chemical information
• Therapeutic assessment of the active pipeline products by stage,
  product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across
  Interleukin-8 (IL-8) Inhibitor

Key Topics Covered:

1. Report Introduction

2. Interleukin-8 (IL-8) Inhibitor – Overview

3. Pipeline Therapeutics

• An Overview of Pipeline Products for Interleukin-8 (IL-8) Inhibitor

4. Comparative Analysis

5. Interleukin-8 (IL-8) Inhibitor Pipeline Products in Clinical
Stages

• Product Description
• Research and Development
• Product Development Activities

6. Interleukin-8 (IL-8) Inhibitor Pipeline Products in
Non-clinical Stages

• Product Description
• Research and Development
• Product Development Activities

7. Therapeutic Assessment: Active Products

• Pipeline Assessment by Route of Administration
• Pipeline Assessment by Stage and Route of Administration
• Pipeline Assessment by Molecule Type
• Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

• Product Description
• Research and Development
• Product Development Activities
• Reason for dormancy/discontinuation

Companies Mentioned

• Genexine
• Dompe Farmaceutici
• Schering-Plough
• AstraZeneca
• Ablynx/Novartis
• Genmab
• Medarex
• Zytoprotec
• TWi Biotechnology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/z08py0

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs